OTCMKTS:PPTDF PeptiDream (PPTDF) Stock Price, News & Analysis $6.95 0.00 (0.00%) As of 10/15/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About PeptiDream Stock (OTCMKTS:PPTDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PeptiDream alerts:Sign Up Key Stats Today's Range$6.95▼$6.9550-Day Range$6.00▼$7.2952-Week Range$5.88▼$12.85VolumeN/AAverage Volume1,120 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PeptiDream Inc. is a Japanese biopharmaceutical company focused on the discovery and development of peptide-based therapeutics. The company uses its proprietary Peptide Discovery Platform System (PDPS) to identify peptides, including highly selective macrocyclic and other nonstandard peptides, that may be developed into medicines for a range of diseases. PeptiDream applies its platform to internal drug-development programs and research collaborations with pharmaceutical and biotechnology companies. Its activities include discovering peptide drug candidates, optimizing their properties, and advancing programs through preclinical and clinical development. The company has also pursued applications involving peptide-drug conjugates and radiopharmaceuticals, in addition to conventional therapeutic peptides. Founded in Japan in 2006 as a company originating from research at the University of Tokyo, PeptiDream serves the global pharmaceutical and biotechnology industry through partnerships and licensing arrangements. Its platform and collaboration model support drug-discovery activities across multiple therapeutic areas and international markets.AI Generated. May Contain Errors. Read More Receive PPTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PeptiDream and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPTDF Stock News HeadlinesPeptiDream’s New Kidney Cancer Trial Adds Radiopharma Upside for PPTDF InvestorsSeptember 18, 2026 | tipranks.comCurium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in JapanJune 11, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 16 at 1:00 AM | Weiss Ratings (Ad)PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration PartnerApril 20, 2026 | businesswire.comPeptiDream Inc. (PPTDF) Q4 2025 Earnings Call TranscriptFebruary 16, 2026 | seekingalpha.comCurium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in JapanFebruary 4, 2026 | globenewswire.comSee More Headlines PPTDF Stock Analysis - Frequently Asked Questions How have PPTDF shares performed this year? PeptiDream's stock was trading at $12.48 on January 1st, 2026. Since then, PPTDF shares have decreased by 44.3% and is now trading at $6.95. How do I buy shares of PeptiDream? Shares of PPTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/16/2026Next Earnings (Estimated)11/11/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PPTDF CIKN/A Webwww.peptidream.com Phone81-4-4270-1300FaxN/AEmployees645Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:PPTDF) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PeptiDream Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PeptiDream With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
